Quantum
Home > Boards > US OTC > Biotechs >

Vivos Inc. (RDGL)

RDGL RSS Feed
Add RDGL Price Alert      Hide Sticky   Hide Intro
Moderator: dshade, i_like_bb_stock, Drugdoctor, benhor, Eltp, Chartmaster
Search This Board: 
Last Post: 11/18/2018 9:38:01 PM - Followers: 807 - Board type: Free - Posts Today: 34

 

Vivos Inc. (OTC: RDGL)

The strategic market sector of Vivos Inc.  is therapeutic isotope applications.  Currently, the Company is engaged in the development of RadioGel™, a Yttrium-90 based brachytherapy device, for the treatment of tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside the treatment area.

The company is engaging the FDA for permission to use RadioGel™ for the treatment of advanced basal and squamous cell skin cancers. The RadioGel™ Veterinary Solutions division of Vivos is focused on demonstrating the safety and therapeutic effectiveness for different animal cancers in four different university veterinary hospitals. Vivos is positioning itself so that after this demonstration phase, The Company can begin to generate revenues through the sale of RadioGel™ to private animal clinics.

The Company currently is outsourcing material aspects of manufacturing of its product in the United States and intends to enter into licensing arrangements outside of the United States for the manufacturing and distribution of RadioGel™ in other countries.

What is RadioGel™?

RadioGel™ is a hydrogel liquid containing tiny Yttrium-90 phosphate particles to be injected into a tumor.  This hydrogel is a liquid at temperatures below body temperature but begins to gel, harden, upon injection as the temperature increases to normal body temperature, thereby locking the particles in place. The particles emit a very high concentrated and contained beta irradiation to kill the tumor. The beta radiation has a short penetration distance so there is minimal collateral damage to healthy tissues outside of the injected area.

RadioGel™ also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days.  This compares favorably to other available treatment options requiring up to 6 weeks or more to deliver a full course of radiation therapy. This is an outpatient treatment much safer to the personnel treating the patient than competing brands and the patient can go home immediately with no risk to family members.

What are the advantages of RadioGel™?

Based upon its studies and analyses, or general application of experience with current brachytherapy devices and Yttrium-90, Vivos believes that its brachytherapy products are likely to offer the following benefits, among others, for patients and medical professionals:

•Maximizing Therapeutic Index: The short-range beta particles emitted by Y-90 deliver radiation energy within a tight range. This enables radiation to be selectively delivered to target tissues while minimizing radiation dose to nearby normal tissues. High therapeutic indices imply that more radiation energy may be imparted to target tissues, with less radiation reaching adjacent normal tissues.

Half-Life: Y-90 has a half-life of just 2.7 days. Many traditional brachytherapy products use isotopes with longer half-lives such as 9.7 days for cesium-131, and sixty days for iodine-125.

•Optimized Delivery Method: Current brachytherapy devices place permanent metal seeds in the prostate by using up to 30 large needles. By contrast, Vivos’s Y-90 RadioGel™ device is designed to be administered in a minimally invasive procedure with small-gauge needles.

•No Permanent Seeds Remaining: Current brachytherapy devices place permanent metal seeds in the tumor. Vivos’s Y-90 RadioGel™ device utilizes a biodegradable, non-toxic polymer that is ultimately absorbed by the body. This eliminates the possibility of a long-term seed migration or other problems that may sometimes arise when seeds remain in the body.

•Good Safety Profile: Many traditional brachytherapy devices utilize isotopes that emit x-rays (akin to gamma radiation). X-rays or gamma radiation travels within and outside of the body and have long half-lives. Vivos’s brachytherapy products use the Yttrium-90 isotope, which is a beta-emitter. Yttrium-90 beta-emissions travel only a short distance and have a short half-life of 2.7 days.

•Potential Lower Cost: Yttrium-90 supplies are readily accessible and are relatively inexpensive. The elimination of the metal or glass enclosures used in traditional brachytherapy seeds greatly reduces manufacturing costs.

What is the market for RadioGel™?

Reliable sources estimate that annual sales of brachytherapy products exceed $2 billion, about half of which are in the United States. The size of the U.S. brachytherapy market for prostate cancer brachytherapy is somewhere between $90 million and $130 million per year. The market for liver and breast cancer combined is comparable.

What is Brachytherapy?

Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area.  According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion.  It is estimated that the U.S. market represents approximately half of the global market.  Vivos believes there are significant opportunities in prostate, breast, liver, pancreatic, head and neck cancers.  The 2013 U.S. estimated new cases according to the American Cancer Society are 240,000 prostate cancer, 235,000 breast cancer, and 31,000 liver cancer.

Are there other markets for RadioGel™? 

March 15th, 2016, Vivos Inc. announced the formation of a new, wholly-owned subsidiary, IsoPet Solutions Corporation, to focus on the vibrant and expanding veterinary oncology market. In August 2017 the subsidiary was changed and made into a separate operating division inside the Company.

The IsoPet™ Veterinary Solutions division will focus on bringing RadioGel™ yttrium-90 brachytherapy products to veterinary oncologists to treat dogs and cats suffering from tumor cancers.

There are over 150 million pet dogs and cats, with over 1/3 of the households in the US owning at least one dog, and just under 1/3 owning at least one cat.  IsoPet
Solutions is establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance. The division will also provide product awareness and education to veterinary oncologists. Initial treatments are to be coordinated through the Chair of the Company’s Veterinary Medicine Advisory Board, Dr. Alice Villalobos.

CEO and President Dr. Mike Korenko stated: “IsoPet Solutions allows specific resources to focus on the use of our RadioGel™ Yttrium-90 brachytherapy products in the veterinary space. We believe that RadioGel™ is positioned to build a significant presence in the cancer treatment tool-kit of veterinary oncologists.”

Dr. Alice stated: "I am quite excited at the opportunity to work with RadioGel's™ team to integrate their products into the cancer treatments of companion animals. Cancer affects 50% of dogs over age ten and one in four dogs under age ten. For many years, we have been searching for a useable and effective agent such as RadioGel™ Y-90 brachytherapy devices that can be delivered into tumors on an outpatient basis. I believe that veterinary oncologists around the globe will finally have an ideal product line for the treatment of accessible and inoperable tumors."

What are the steps for FDA clearance?

Vivos met at the FDA offices to discuss next steps, expectations and required testing to progress towards obtaining marketing clearance for the Y-90 RadioGel™ device. The FDA and Vivos management and consulting team are working closely in order to obtain all appropriate data and benchmarks the FDA requires in order to proceed with providing final clearance for marketing the device in the United States.

August 2016, Vivos announced a partnership with IsoTherapeutics Group, a third-party radiopharmaceutical R&D company, to provide commercialization support and conduct additional studies as requested by the FDA for the Y-90 RadioGel™ device. IsoTherapeutics has completed the first stage of the project, comprised of tech transfer, manufacturing and in vitro testing. The next stage, comprised of additional in vitro and in vivo testing. Upon completion of these studies, Vivos anticipates submittal (direct De Novo) for FDA clearance for full commercialization in the U.S. (see company press releases for continual updates on this evolving process).
 



Press Releases 2018 ( Change in Company name and trading symbol • Jan 2, 2018)
Jan 2, 2018,  Advanced Medical Isotope Corporation (ADMD) Announces Corporate Name Change to Vivos Inc., and Ticker Symbol Change to RDGL
 



Press Releases 2017 ( Change in Management & Directors Dec 2016)

Dec 20, 2016,  AMIC's Board of Directors Appoints Dr. Michael Korneko CEO and Dr. Carlton Cadwell Chairman of AMIC
Jan 11, 2017,  AMIC's New CEO Issues Letter to Shareholders
Feb 14, 2017,  AMIC's CEO Releases Shareholder Letter Outlining New Streamlined Path to FDA Submission
Feb 28, 2017,  AMIC's New CEO Releases Shareholder Letter Announcing and Discussing their Cancer Indication Selection to pursue FDA Approval
Mar 7, 2017,  AMIC's New CEO Releases Shareholder Letter Detailing Launch of Veterinary Oncology Division with Radiogel
Mar 23, 2017,  Update on Feline Cancer Treatment and Improvement to Financial Structure
Jul 6, 2017,  AMI Requests Pre-Submission Meeting with FDA
Jul 11, 2017,  ADMD Makes Significant Improvement to its RadioGel™ Brachytherapy Product
Jul 27, 2017,  ADMD to Host Shareholder Update Webcast with Live Q&A
Aug 2, 2017,  Advanced Medical Isotope Corp. Announces Results of Shareholder Meeting, Welcomes Two New Members of the Board of Directors
Sep 14, 2017,  Advanced Medical Isotope Corporation has its first discussions with private animal consortiums to utilize RadioGel™


Independent Analyst Research and Price Target

Sep 7, 2017, Van Leeuwenhoek Research Increases Valuation of ADMD to USD $35-$55 million USD or $0.66 - $1.00 per share


Presentation(s) from CEO & President, Dr. Mike Korenko.

2017 -  LINK HERE



STOCK SYMBOL: OTC: RDGL

COMPANY WEBSITE
FACEBOOK
TWITTER

UPDATED 8/24/2017

https://www.otcmarkets.com/stock/RDGL/security

Vivos Inc Signs Memorandum of Understanding with Private Veterinary Hospital as Pilot Clinic for Commercial IsoPet® Therapy
https://www.otcmarkets.com/stock/RDGL/news/story?e&id=1184491
Richland, WA, Oct. 02, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) selected its first clinic for commercial sales of IsoPet

Vivos Inc., a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in humans and animals, announced today that the Vista Veterinary Hospital in Kennewick WA, located near Vivos’ headquarters, has been selected for the commercial launch of IsoPet® therapy. After several meetings with the clinic’s veterinarian owners, a Memorandum of Understanding has been signed.

Vivos’ strategy is to partner with several regional clinics across the country using this pilot program to provide practical experience to be shared with other potential regional clinic partners. Having selected a local clinic as the pilot provider of IsoPet™ therapy will make for cost-effective frequent site visits for the assistance of facility set-up, certification training, and radioactive material handling licensing. Certification training and the process of acquiring a Radioactive Material License for the clinic from the Washington State Department of Health has begun.

It is expected that as the successful results of the therapies become known, pet owners from as far as Spokane, Seattle and Portland will seek to have their affected animals treated at the Vista Clinic. It is estimated that more than 9 million people live within 250 miles of Kennewick.

Dr. Mike Korenko, Vivos CEO stated “Best management practice dictates that we pilot partnering with a private clinic prior to expanding to other regional clinics across the county. We will gain practical experience, such as the effectiveness of our certification training and the time and effort required to obtain the Radioactive Material License. This will optimize the process of engaging with other treatment centers”.

As noted in a previous press release, the company will introduce IsoPet® to the larger veterinarian community at the annual Veterinary Cancer Society Conference to be held in Louisville, KY October 17-20, 2018.

About Vivos Inc. (OTC: RDGL)

Vivos, Inc. has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (IsoPet®) and in humans (Radiogel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel formulation. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

IsoPet® for treating animals uses the same technology as RadioGelTM for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

IsoPet® is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.

The IsoPet® Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will begin in the near future.

The Company recently obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Following this demonstration phase, Vivos can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private veterinary clinic consortiums.

The Company is also engaging the FDA for clearance to market RadioGel™ for the treatment of advanced basal and squamous cell skin cancers in humans.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

CONTACT:

Vivos Inc.
Michael K. Korenko, President & CEO
MKorenko@RadioGel.com

Source: Vivos Inc.

            © 2018 GlobeNewswire, Inc.

First Successful Treatment of Canine Sarcoma using IsoPet® to be Presented at Veterinary Cancer Society Conference
https://www.otcmarkets.com/stock/RDGL/news/story?e&id=1180102

Richland, WA, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC PINK: RDGL) first therapy to canine treat soft tissue sarcoma is successful

Vivos Inc, a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in humans and animals, is pleased to report several significant outcomes after its signature product, IsoPet®, was used to treat a hind-leg soft-tissue sarcoma in a Sheltie at the University of Missouri Veterinary Health Center in Columbia, Missouri.

Veterinary oncologist, Dr. Charles Maitz, reported that the treatment of the sarcoma resulted in a “complete response,” meaning tumor destruction and disappearance, together with a healthy recovery. Results will be presented in at the Veterinary Cancer Society’s annual conference in Louisville, Kentucky, October 17 – 20, 2018.

After therapy the pet owner commented that the dog had more energy than she can remember for a long time. “The owner is delighted!” said Dr. Maitz.

Study investigators were also pleased that IsoPet® met all RadioGel™ design performance criteria. Post-treatment imaging and dosimetry provided confirmatory data addressing the principal questions previously raised by an FDA review panel, including:

    Near-uniform placement by injection and interstitial perfusion within the tumor without vascular clearance to normal organs and tissues
    Very high therapeutic ratios (radiation dose to the tumor relative to normal organs)
    Effective, highly localized, high-dose radiotherapy, and complete absence of adverse side-effects in critical normal tissues

The University of Missouri is now advertising availability of IsoPet® treatment for dogs and other species, including treatment of equine (horse) sarcoids.

Mike Korenko, Vivos Inc CEO stated “The successful treatment of the cat and dog subjects thus far increases the likelihood of IsoPet® becoming a practical solution in the treatment of animal cancer. Additionally, the data obtained at the University of Missouri will support the pre-clinical investigations required by the FDA to provide evidence that RadioGel™ can be safe and effective for treating various human cancers.”

About Vivos Inc. (OTC: RDGL)

Vivos, Inc. has developed an yttrium-90-based brachytherapy injectable device for treating tumors in animals (IsoPet®) and in humans (Radiogel™). Brachytherapy employs highly localized minimally invasive radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel formulation. The injections deliver therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

IsoPet® for treating animals uses the same technology as RadioGelTM for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

IsoPet® is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.

The IsoPet® Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will continue.

The Company recently obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Following this demonstration phase, Vivos can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private veterinary clinic consortiums.

The Company is also engaging the FDA for clearance to market RadioGel™ for the treatment of advanced basal and squamous cell skin cancers in humans.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

CONTACT:

Vivos Inc.
Michael K. Korenko, President & CEO
MKorenko@RadioGel.com

Source: Vivos Inc.

            © 2018 GlobeNewswire, Inc.

Amending and Replacing the Initial Press Release on George Sharp; Disregard the first release:
https://www.otcmarkets.com/stock/RDGL/news/story?e&id=1179493

Richland, WA, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Vivos Inc. (OTC: RDGL), a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in humans and animals, today announced that it has retained well-known microcap analyst and consultant, George Sharp, as an advisor to the company. Mr. Sharp will advise Vivos on its business strategy, financing endeavors and its commitment to investor interests.

Vivos Inc. President, Mike Korenko, stated, “As we discovered from an unsolicited July 17, 2018 article written by George and posted on his blog, George is very supportive of our efforts towards developing cancer treatments, and to date, Vivos remains the only microcap issuer that he has ever endorsed.”

Mr. Korenko went on to say, “George's experience as an advocate for individual investors in the microcap space, has garnered him a significant following, and his respect is a commodity valued by Vivos. We look forward to George’s continued contribution as we endeavor to execute on the agreements outlined in our previous press release to eliminate the toxic debt and provide critical funding for product development.”

"I am thrilled for the opportunity to work with Vivos’ management and I am encouraged by their dedication to create a valuable company that can improve therapeutic results and quality of life for those needing treatment and reward investors for their support of this important effort. This is a genuine commitment rarely found within the OTC Markets”, stated George Sharp. "I look forward to making my small contribution towards finding less invasive treatments for cancer through my continued support of the company."

About Vivos Inc. (OTC: RDGL)

Vivos, Inc. has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (IsoPet®) and in humans (Radiogel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel formulation. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

IsoPet® for treating animals uses the same technology as RadioGelTM for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

IsoPet® is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.

The IsoPet® Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will begin in the near future.

The Company recently obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Following this demonstration phase, Vivos can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private veterinary clinic consortiums.

The Company is also engaging the FDA for clearance to market RadioGel™ for the treatment of advanced basal and squamous cell skin cancers in humans.

About George Sharp

Drawing from his experiences as a litigant, investigator and forensic researcher, George Sharp consults with attorneys and publicly-traded companies seeking to protect investors. He has appeared on television and referenced in the print media for his efforts to combat microcap fraud. To learn more about George Sharp's services, visit www.clippercp.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

CONTACT:

Vivos Inc.
Michael K. Korenko, President & CEO
MKorenko@RadioGel.com

Source: Vivos Inc.

            © 2018 GlobeNewswire, Inc.

Vivos Inc Retains Well-Known Analyst, George Sharp, as Advisor - Updated
https://www.otcmarkets.com/stock/RDGL/news/story?e&id=1179363
Richland, WA, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Vivos Inc. (OTC: RDGL), a pharmaceutical company in the process of researching and developing minimally invasive treatments to combat cancer in humans and animals, today announced that it has retained well-known microcap analyst and consultant, George Sharp, as an advisor to the company.   Mr. Sharp will advise Vivos on its business strategy, financing endeavors and its commitment to investor interests.

Vivos Inc. President, Mike Korenko, stated, “As we discovered from an unsolicited July 17, 2018 article written by George and posted on his blog, George is very supportive of our efforts towards developing cancer treatments, and to date, Vivos remains the only microcap issuer that he has ever endorsed.”

Mr. Korenko went on to say, “George's experience as an advocate for individual investors in the microcap space, has garnered him a significant following, and his respect is a commodity valued by Vivos.  We look forward to George’s continued contribution as we endeavor to execute on the agreements outlined in our previous press release to eliminate the toxic debt and provide critical funding for product development.”

"I am thrilled for the opportunity to work with Vivos’ management and I am encouraged by their dedication to create a valuable company that can improve therapeutic results and quality of life for those needing treatment and reward investors for their support of this important effort.  This is a genuine commitment rarely found within the OTC Markets”, stated George Sharp. "I look forward to making my small contribution towards finding less invasive treatments for cancer through my continued support of the company."

About Vivos Inc. (OTC: RDGL)

Vivos, Inc. has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (IsoPet®) and in humans (Radiogel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel formulation. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

IsoPet® for treating animals uses the same technology as RadioGelTM for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

IsoPet® is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.

The IsoPet® Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will begin in the near future.

The Company recently obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Following this demonstration phase, Vivos can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private veterinary clinic consortiums.

The Company is also engaging the FDA for clearance to market RadioGel™ for the treatment of advanced basal and squamous cell skin cancers in humans.

About George Sharp

Drawing from his experiences as a litigant, investigator and forensic researcher, George Sharp consults with attorneys and publicly-traded companies seeking to protect investors.  He has appeared on television and referenced in the print media for his efforts to combat microcap fraud. To learn more about George Sharp's services, visit www.clippercp.com.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

CONTACT:

Vivos Inc.
Michael K. Korenko, President & CEO
MKorenko@RadioGel.com

Source: Vivos Inc.

            © 2018 GlobeNewswire, Inc.

Vivos Inc Signs a Standstill Agreement with Debt Holders Designed to Halt the Toxic Selling and Eliminate the Secured Toxic Debt
https://www.otcmarkets.com/stock/RDGL/news/story?e&id=1177528
Richland WA , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTC PINK: RDGL)

Vivos Inc is pleased to announce that all the debtholders of Vivos’ secured convertible debt have agreed to a ten trading day market standstill, during which time they agree to refrain from any conversions or to trade in our security. The market standstill will be in effect from Wednesday September 26th through Wednesday October 10. Pursuant to the terms of the agreement, and subject to completion of a capital raise with proceeds of at least $500,000, the remaining outstanding balance on these secured debentures, which totals approximately $2,500,000 of principal and accrued interest, will automatically convert into common stock (or convertible preferred stock for conversions that would result in ownership in excess of 4.99% of the company’s common shares) at a fixed conversion price of $.004. These shares will be subject to a restriction on any sales below $.02 through December 31, 2018 and will have volume limitations on any sales below $.01 for the first six months of 2019.

Mike Korenko, Vivos Inc CEO, stated “It is our goal for the new capital to come in the form of common stock and warrants. In addition, we may consider additional financing in the form of convertible debt that automatically converts into a larger equity financing or converts at a fixed conversion price. Upon the successful completion of these transactions we plan to have a company free of convertible toxic debt moving forward. We are confident that we will be successful, but there is no guarantee that we will complete the transactions described above. We look forward to providing an update related to the financing in the next couple of weeks and we will continue to communicate developments related to Isopet® and Radiogel™.”

About Vivos Inc. (OTC: RDGL)

Vivos, Inc. has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (IsoPet®) and in humans (Radiogel™). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel formulation. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

IsoPet® for treating animals uses the same technology as RadioGelTM for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

IsoPet® is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.

The IsoPet® Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will begin in the near future.

The Company recently obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Following this demonstration phase, Vivos can begin to generate revenues through the sale of IsoPet® to University animal hospitals and private veterinary clinic consortiums.

The Company is also engaging the FDA for clearance to market RadioGel™ for the treatment of advanced basal and squamous cell skin cancers in humans.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

CONTACT:

Vivos Inc.
Michael K. Korenko, President & CEO
MKorenko@RadioGel.com

Source: Vivos Inc.

            © 2018 GlobeNewswire, Inc.

Vivos Inc Signs a Standstill Agreement with Debt Holders Designed to Halt the Toxic Selling and Create a Debt Free Company
https://www.otcmarkets.com/stock/RDGL/news/story?e&id=1177256
Richland WA, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Vivos, Inc. (OTC PINK: RDGL)

Vivos Inc is pleased to announce that all the debtholders of Vivos convertible debt have agreed to a 10 day standstill, during which time they agree not to convert any more debt into common stock as well as not trade in our security. The purpose of the standstill agreement is to give Vivos time to raise new capital. As part of the standstill agreement, the debtholders will agree to remove the variable rate convertible features from their debt upon the successful completion of the capital raise and convert the balance of their debt into common stock and preferred stock at a fixed price. The new capital coming in would also be common stock, not variable rate convertible debt. Upon the successful completion of these transactions we plan to have a company that is debt free moving forward. We are confident that we will be successful but there is no guarantee that we will complete the transactions. We look forward to providing updates in the next couple of weeks.

About Vivos Inc. (OTC: RDGL)

Currently, the Company has developed an Yttrium-90 based brachytherapy device, for the treatment of tumors in animals and humans. Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The product delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

IsoPet® for treating animals uses the same technology as RadioGelTM for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

IsoPet® is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.

The IsoPet® Solutions division of RDGL is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will begin in the near future.

The Company recently obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. RDGL is positioning itself so that immediately following this demonstration phase, The Company can begin to generate revenues through the sale of IsoPetTM to University animal hospitals and private veterinary clinic consortiums.

The Company is also engaging the FDA for clearance to market RadioGelTM for the treatment of advanced basal and squamous cell skin cancers in humans.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

CONTACT:

Vivos Inc.
Michael K. Korenko, President & CEO
MKorenko@RadioGel.com

Source: Vivos Inc.

            © 2018 GlobeNewswire, Inc.

Vivos Inc Sets the Stage for the Introduction of IsoPet® (RadioGel™) to the Veterinarian Community
https://www.otcmarkets.com/stock/RDGL/news/story?e&id=1141383
Richland, WA, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) finalizes its plan to introduce IsoPet® to the veterinarian community.

IsoPet® was designated as a device by the FDA and the Center for Veterinary Medicine has reviewed Vivos’ labeling and instructions for use for treating feline and canine sarcomas. This means that we have the green light to sell our product commercially for veterinary use. We believe that it is prudent to first complete the clinical study currently underway at the University of Missouri using IsoPet® to treat canine sarcomas. We are projecting the IsoPet® product debut by October of this year to allow time to collect more data on this indication for use.

The first product introductory step was recently accomplished by Dr. Alice Villalobos, Chair of our Veterinary Medicine Advisory Board. She has just published the 2nd edition of her book entitled, Canine and Feline Geriatric Oncology: Honoring the Human-Animal Bond. It is considered the “Bible” of Veterinary Oncology and features IsoPet®/RadioGel in three separate places.

An important vehicle for engaging thought leaders and early adopters in the veterinary community is through professional society conferences. The two premier conferences are annual meetings of the Veterinary Cancer Society (VCS) and the American College of Veterinary Radiology (ACVR). Attendance at these conferences will allow us to reach hundreds of veterinarians across the country and internationally.

    Dr. Charlie Maitz, our principal investigator for canine sarcoma at the University of Missouri, will deliver a key-note presentation on the State of the Art of the Therapeutic use of Nuclear Medicine at the ACVR annual meeting in October 2018. He is anxious to discuss IsoPet in that important forum.  
    Vivos Inc is a bronze contributor and will have a booth at the annual VCS conference in October 2018. The VCS has just confirmed that our paper was accepted. It will summarize our therapies of feline sarcoma at Washington State University and canine soft tissue sarcomas at the University of Missouri. Dr. Janean Fidel from Washington State University, Dr. Charles Maitz from the University of Missouri and Dr. Darrell Fisher are co-authors. As a co-author and a member of the VCS I will be presenting the paper. I am also the introductory speaker for another presentation. This will be the first wide exposure of the veterinarian community to IsoPet.

Dr. Philip Bergman, a Director at VCA, one of our potential private clinic consortium partners, emphasized the importance of publishing in the VCS proceedings.

Mike Korenko, Vivos CEO, said, “Our intent is to use the VCS conference to identify a list of initial users of IsoPet®. We plan to select the optimum candidates in each of our targeted regions across the United States. We will offer to provide certification training and assist them in obtaining their radioactive material handling licenses. I am excited to be taking this important step. The animal testing has a dual purpose. It is also a key pre-clinical test to support human skin cancer therapy.”

About Vivos Inc. (OTC: RDGL)

Currently, the Company has developed an Yttrium-90 based brachytherapy device, for the treatment of tumors in animals and humans. Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The product delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.

IsoPet® for treating animals uses the same technology as RadioGelTM for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.

IsoPet® is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.

IsoPet® also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.

The IsoPet® Solutions division of RDGL is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will begin in the near future.

The Company recently obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. RDGL is positioning itself so that immediately following this demonstration phase, The Company can begin to generate revenues through the sale of IsoPetTM to University animal hospitals and private veterinary clinic consortiums.

The Company is also engaging the FDA for clearance to market RadioGelTM for the treatment of advanced basal and squamous cell skin cancers in humans.

Safe Harbor Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

CONTACT:

Vivos Inc.
Michael K. Korenko, President & CEO
MKorenko@RadioGel.com

Source: Vivos Inc.

            © 2018 GlobeNewswire, Inc.

 

Quantum
RDGL
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
#99554   RDGL-Advisor George Sharp is all about protecting investors.. TruthFairy222 10/14/18 07:00:15 PM
#109877   Board MDs from Cedar Sinai and Mayo Clinic dshade 11/12/18 10:45:23 AM
#107793   RDGL is backed by 2 different major Universities.. TruthFairy222 10/31/18 02:36:37 PM
PostSubject
#110110  Sticky Note wowsa another form 4 for almost 32M shares i_like_bb_stock 11/13/18 08:54:09 AM
#109154  Sticky Note Sharp as advisor for RDGL and PLFM benhor 11/09/18 10:00:41 AM
#109109  Sticky Note IsoPet-Dog-#2-"MOOSE"-Pictures-of-CANCER-CURE-From-Owners-Facebook-page Drugdoctor 11/08/18 08:56:21 PM
#106407  Sticky Note $RDGL NEWS OUT!!!!!! Vivos Inc. Successfully Administers IsoPet® PennyStockTroll 10/26/18 08:09:01 AM
#99495  Sticky Note The groundbreaking cancer treatment, how it works.. TruthFairy222 10/14/18 04:14:49 PM
#65430  Sticky Note Radiogel, Radiogel for Vet will be a major obesestupidmouse 08/05/17 07:15:12 PM
#110988   The rising 50 day MA support is coming Chartmaster 11/18/18 09:38:01 PM
#110987   Expecting big breakout this week! $RDGL Chartmaster 11/18/18 09:36:53 PM
#110986   If they actually viewed the video and added gonetopot 11/18/18 09:22:04 PM
#110985   Thanks Drugdoctor for the update. It only reinforces ali12 11/18/18 08:27:09 PM
#110984   All the tests have gone positive, should be sharky 11/18/18 08:00:30 PM
#110983   yes,people did not do this yet, please do, bdvest 11/18/18 07:45:10 PM
#110982   hope good news release before Thanksgiving! bdvest 11/18/18 07:40:26 PM
#110981   Handjob: You should bail and find a better gonetopot 11/18/18 06:57:33 PM
#110980   Listen this company has not made one claim gonetopot 11/18/18 06:55:28 PM
#110979   Yes, or a progress report from $RDGL on Drugdoctor 11/18/18 05:36:54 PM
#110978   It was fake one! Last time, someone already handMMJ 11/18/18 05:34:30 PM
#110977   Anyone know what if anything happened with distribution Albear 11/18/18 05:26:45 PM
#110976   Excellent, another canine saved from cancer! TruthFairy222 11/18/18 04:46:46 PM
#110975   I do agree with you on that. I HoneyBager 11/18/18 03:11:55 PM
#110974   I am not a stock Guru, but it gonetopot 11/18/18 02:54:11 PM
#110973   I am not skeptical. My initial entry here bcarefulwhatuwish4 11/18/18 02:35:54 PM
#110972   Sounds right. Bushmantrader 11/18/18 02:15:18 PM
#110971   The only concern I have is the shares HoneyBager 11/18/18 02:13:05 PM
#110970   The video points out the fact that it gonetopot 11/18/18 02:09:27 PM
#110969   All investors and skeptical people need to watch gonetopot 11/18/18 01:56:13 PM
#110968   How much will George do for US, he slow trolling 11/18/18 01:44:39 PM
#110967   George is always quiet before the storm... Arch_Investor 11/18/18 01:32:56 PM
#110966   Your right (gone), he knows this teck works, sharkey1 11/18/18 12:08:15 PM
#110965   I don't think he would have let the gonetopot 11/18/18 11:49:32 AM
#110964   I hope we get a tweet from George sharkey1 11/18/18 10:32:10 AM
#110963   I thought someone had said that the Facebook 714 11/18/18 10:29:01 AM
#110962   Exactly... they put that big cone around their Drugdoctor 11/18/18 08:47:25 AM
#110961   Absolutely.... it's working... All surgeries drain, then heal... Drugdoctor 11/18/18 08:45:42 AM
#110960   Check my math isn't 625 million shares x gonetopot 11/18/18 08:26:14 AM
#110959   Yes, sometimes with positive margins, re-resection, and skin grafts LDIGGIDY 11/18/18 08:23:39 AM
#110958   I have to agree with you. I Bushmantrader 11/18/18 06:52:11 AM
#110957   I might add, she said the same thing sharkey1 11/18/18 05:16:56 AM
#110956   That's wonderful, I on imangin it itches. And sharkey1 11/18/18 04:00:16 AM
#110955   Moose's wound is draining now... that's GOOD NEWS.... Drugdoctor 11/18/18 02:08:19 AM
#110954   The annual cost of treating skin cancers in gonetopot 11/17/18 10:34:39 PM
#110953   Many can't just be cut off. Do research gonetopot 11/17/18 10:33:12 PM
#110952   Thanks Chief RiverNorth0x 11/17/18 08:11:39 PM
#110951   I wonder how George is doing in Canada.. TruthFairy222 11/17/18 08:04:11 PM
#110950   It's for new eyes.. TruthFairy222 11/17/18 07:58:18 PM
#110948   All the noise lol... Dollars coming watch & pennylandspirit 11/17/18 06:22:36 PM
#110944   You do know people get skin cancer removed Pennydream 11/17/18 04:04:15 PM
#110943   Wow, sounds politico correct now on Rdgl! It handMMJ 11/17/18 02:35:05 PM
#110941   That be great! I take it all! handMMJ 11/17/18 02:10:06 PM
#110938   Hmm, Frankly speaking, there will not be enough sharkey1 11/17/18 01:47:08 PM
#110937   Frankly speaking,Rdgl is worth to bet , worth handMMJ 11/17/18 01:20:41 PM
#110935   Trying to connect the dots. Should I Malibew66 11/17/18 12:59:09 PM
#110934   Hopefully ur Right, basically, Rdgl takes so long handMMJ 11/17/18 12:42:46 PM
#110933   Exactly $$$$$$$$$$$$ pennylandspirit 11/17/18 12:13:01 PM
#110932   All news coming from RDGL will be good gonetopot 11/17/18 11:50:31 AM
#110931   Hard to say “uptrend”, without any good news, handMMJ 11/17/18 11:44:54 AM
PostSubject